INTRODUCTION
Bipolar disorder (BD) type I is a chronic disease characterized by recurrent episodes of mania and depression; these episodes impair in functioning and reduce health-related quality of life. BD requires both acute and maintenance therapy [1] . Several guidelines for the treatment of acute manic states have been published: all of them, consensually, indicate that first-line treatment should be monotherapy [2] [3] [4] [5] [6] . They all recommend that the initial treatment for manic episodes should be lithium (Li), valproate (VPA) an atypical antipsychotic (AAP) of other monotherapy. All these expert guidelines agree that any ongoing antidepressant medication should be withdrawn during mania. Combinations are suggested by most guidelines as second-line choice, although in some as first-choice approach for severe mania.
Clinical practice differs from guideline recommendations. Only one in six bipolar patients is discharged on monotherapy medication recommended by the guidelines [7] .
Indeed, in routine practice, monotherapy is not sufficient in many cases to obtain a significant reduction in symptoms and/or to effectively prevent relapse, and less than 10% of BD patients receive monotherapy during acute mania episodes [8, 9] . Thus, there has been a consistent increase in the use of combination therapy (or polypharmacotherapy) and this is observed worldwide [10] . Wolsfsperger and colleagues showed that polypharmacy is a common phenomenon in treatment of acute mania; they report that the mean number of psychopharmacological agents prescribed per patient is 3.3 ± 1.5, and confirmed that this has increased with time since 1994 [9] .
The recent scientific literature also contains various evidence of the better efficacy of combination therapy in manic phases [8] . Our analysis focuses on the efficacy of combination treatment in manic episodes and reviews major pertinent randomized controlled studies.
METHODS
We conducted an extensive search for relevant national and international controlled studies, treatment guidelines and comprehensive reviews published since 1980. The publications were obtained from the Medline electronic database. The literature search was performed using the Mesh heading: "bipolar disorder" OR "manic" OR "mania" AND "combination" OR "adjunction" OR "treatment algorithms". The search was updated until May, 11st, 2012. Only articles written in English were considered as eligible. The figure 1 shows details of the review methods and the search strategy. We included all randomized, double-blind trials comparing one combination (or adjunction) treatment including active antimanic drugs at a therapeutic dose with another active antimanic drug in monotherapy or with placebo as therapy for adults with acute mania. Fifty-nine studies and reviews were included in the qualitative analysis (see figure 1 for details).
- Figure 1 about hereStrategies of combination treatment for manic phases
Guidelines
The primary goals of treatment of a manic episode are the rapid control of symptoms such as agitation, impulsivity or dangerous behavior, and to allow a return to normal levels of psychosocial functioning [3, 4] . Recovery is a multidimensional concept that includes both symptomatic recovery (remission) and functional recovery. In the longitudinal EMBLEM prospective study, 64% of BD type I patients achieved remission and 34% achieved functional recovery [11] . This study showed that patients who presented with acute mania and who took typical antipsychotics or antidepressants for the long-term treatment phase (12 weeks), had lower remission and recovery rates; prescription of APA was associated with a better remission rate [11] . In addition to the rapidity of symptom control, the issues of tolerability and side-effects of treatment need to be considered.
In guidelines [2] [3] [4] [5] [6] , favor monotherapy as the first-line approach, for safety and practicability reasons; they recommend making best use of the dose range available for a given medication, since combined treatment is likely to be associated with a cumulated and thus higher frequency and severity of side effects [8] [3] and as a second choice for cases of mild and moderate mania after unsuccessful medication in the others guidelines [8] . The American Psychiatric Association guidelines for treating BD recommend combination therapies to treat patients experiencing severe acute manic or mixed episodes and breakthrough manic or mixed episodes during maintenance therapy [12] . However, combination treatment, involving two or more antimanic agents, is routinely used for acute mania episodes in a large majority of BD patients. This divergence between guidelines and clinical practice is probably due to the complexity of the disease, comorbidity and lack of adherence [11] .
Clinical trials
Randomized controlled trials (RCT) of combination therapy for the treatment of acute mania are summarized in Table 1 . Only randomized, double-blind, controlled studies were included .
There are very few recent RCT that compare different combination therapies for the treatment of acute manic phases [35] . As combinations are widely used, it would be valuable to compare combination therapies not only to monotherapy but also to others types of combination. This should be the next step of evaluations of the treatment of manic phases.
- Table 1 Also, the study found that haloperidol, olanzapine, risperidone and quetiapine as co-therapy were significantly more effective than monotherapy with a mood stabilizer against mania, but that combinations were less well tolerated than monotherapy [38] . These results confirm the benefits of including an antipsychotic in the treatment if the patient does not fully respond to a mood stabilizer alone.
The superiority of combinations over monotherapy has been demonstrated, validating current clinical practice. The management of acute mania requires antimanic medications that ensure safety and rapid suppression of the cognitive, behavioral, and psychotic symptoms occurring during episodes. The superior efficacy and speed of action of combinations have led some authors to propose the systematic use of a combination as a first line option [8] . It is therefore important to study the long-term effects of these drug combinations in terms of tolerance and preventing relapse.
Combination therapy and prevention to relapse
The primary goal of maintenance therapy is to achieve symptomatic and then functional remission and to prevent relapse of any pole, but mostly the acute pole [12] . Several recent studies have documented the superiority of combination products for the prophylactic treatment phase. Mood stabilizers have various profiles of efficacy and tolerability, suggesting that they could have complementary roles in long-term maintenance treatment and the prevention of relapse [39] . A recent review of randomized trials found that Li, lamotrigine (LAM), olanzapine (OLZ) and VPA, were each more effective than placebo at preventing relapse to any mood episode. Li and OLZ significantly reduced manic relapses [39] .
Numerous studies, summarized in Table 2 [34, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] , show that the time to relapse to any mood episode was longer under continuation of APA and Li or VPA treatment than Li or VPA monotherapy. These findings suggest that there is a long-term benefit in continuing APA as an adjunct to a mood stabilizer after sustained remission is achieved. Vieta et al.
reported meta-analysis examining the efficacy of maintenance treatments for BD. Of the combination treatments studied, ziprasidone with Li or VPA and risperidone with Li or VPA significantly reduced the risk of a manic relapse, and only quetiapine with Li or VPA significantly reduced the risk for relapse at both the manic/mixed and depressed poles of BD [52] . However, the continued use of a typical antipsychotic following remission from acute mania was associated, in the study by Zarate et al., with a shorter time to depressive relapse, more depressive symptoms, higher rates of dysphoria and Parkinsonism, and greater discontinuation rates. These findings imply that the continued use of typical antipsychotics following remission from mania might be detrimental for the depressive pole [50] . Thus, maintenance of APA after a manic phase is controversial: it may reduce the risk of manic relapse, but also shorten the time to depressive relapse. This option therefore needs to be considered in the light of the disease course and predominant polarity of each patient.
Quetiapine might be a useful option in cases of depressive-predominant polarity. Combination treatment with aripiprazole in situations of addictive comorbidities in BD may be particularly beneficial [53] . An open study investigated replacing the previous antipsychotic treatment with aripiprazole in patients treated for BD or schizoaffective disorder who displayed signs of substance abuse; this treatment resulted in a significant reduction in the craving for alcohol and cocaine over a 3-month follow-up [54] . Finally, age at onset of BD has been proposed to be a prognostic marker of the response to treatment and should be considered for future treatment clinical trials [55] .
Further studies are needed to confirm these various preliminary results and may contribute to the development of more personalized therapies for acute and maintenance manic phases.
- Table 2 about hereIn summary, the time to recurrence of any event (mania, depression, or mixed) in manic episode seems to be longer under combination maintenance treatment, especially with APA in combination with Li/VPA, than under placebo with Li/VPA. However, this notion is disputed because the continued use of typical antipsychotics following remission from mania has been observed by Zarate and colleagues to be detrimental for the depressive pole [50] .
Combination treatments can provide an effective long-term option for bipolar disorder to prevent recurrences of mania and/or depressive episodes but may lead to residual depressive symptoms. In addition to considerations of long-term effectiveness, the issues of tolerability and side-effect profile of combination treatments need to be addressed. The meta-analysis of Cipriani et al. concluded that among antimanic drugs , risperidone, olanzapine and haloperidol are the best of the available options for the treatment of manic episodes [37] . Unfortunately, these results were obtained by pooling data from both monotherapy and combination studies, and no separate analysis of efficacy and acceptability of combined therapies alone is provided. The efficacy of a drug as an adjuvant can be assessed more reliably from analysis of its combination with placebo than with another active drug; the results of studies involving combinations of two or more drugs should therefore be interpreted with caution [58] . Although the efficacy of olanzapine is good, its tolerability profile is marked by a possible rapid weight gain and metabolic syndrome; these issues have led to the guidelines of WFSBP recommending decreased use of olanzapine [2] .
There is insufficient data available about combination therapies and their tolerability profiles; Table 3 provides an overview of RCT reporting safety and tolerability data for various combinations [21] [22] [23] [24] [25] 29, 30, 34, 41, 42, 44, 45, 48 ].
- Table 3 about here -
The patterns of safety and tolerability differ between types of combination. The whole sample of combinations exhibited more side effects than monotherapy, and higher discontinuation rates due to adverse events (rate range of 1.9 to 17% for combination versus 0 to 13.3% for Li/VPA monotherapy). Weight gain is particularly significant for combinations including olanzapine (mean range of +2 to +3.04 kgs for combination versus -1. The primary therapeutic objective of maintenance therapy is to prevent relapse and recurrence of acute mood events. As patients are likely to receive maintenance treatment for long periods, the tolerability of these agents is an important consideration. One APA with Li/VPA combination shows the best efficacy with acceptable safety and tolerability. Specific adverse events, and in particular weight gain and sedation, need to be evaluated before initiating an adjunctive or combination therapy and to be monitored after its introduction.
CONCLUSION
The first-line approach to manic phases in all the guidelines we examined is monotherapy, with combination therapies being reserved for severe cases or as a second choice. In real-life practice, monotherapy is often not sufficient during acute and/or maintenance therapy. Consequently, most patients are administered combination therapies.
There is currently no appropriate algorithm involving different combination treatments, the phase of the illness and specific clinical presentations despite the very common phenomenon of combined prescriptions. This review of literature leads us to suggest that combination therapy with APA and Li or VPA could be used as a first-line approach because it is more effective than monotherapy for treatment during the acute phase. The use of combinations during maintenance phases requires prudence and careful consideration of tolerability and the safety profile. Each combination and should be evaluated on an individual basis. Future guidelines need to include suitable algorithm to help decision-making concerning the use of combination treatment.
ACKNOWLEDGMENTS
Research funding relating to this study was obtained from Assistance Publique-Hôpitaux de Paris, Paris, France (PAG).
DISCLOSURE:
PAG declares no conflict of interest regarding the present study and has received no compensation for professional services in the two years prior to submission of this paper. BE, CH and FB have received honoraria and financial compensation as independent symposium speakers from Sanofi-Aventis, Lundbeck, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, and Servier. > = more effective; ALP = allopurinol; ARI = aripiprazole; ASE = asenapine; BZD = benzodiazepines; CBZ = carbamazepine; GBP = gabapentine; HAL = haloperidol; LAM = lamotrigine; LEV = levomepromazine; Li = lithium; MS = mood-stabilizer (lithium or valproate); OLZ = olanzapine; PBO = placebo; PER = paliperidone extended-release; QTP = quetiapine; RSP = risperidone; SND = standard neuroleptic drug; TXF = tamoxifen; VPA = valproate. RCT = randomized controlled trial. Li > = Combination is more effective than monotherapy in terms of relapse; ARI = aripiprazole; ASE: asenapine; BZD = benzodiazepines; CBZ = carbamazepine; LAM = lamotrigine; Li = lithium; NS = not statistically significant; NR = not reported; OLZ = olanzapine; OXC = oxcarbazepine PBO = placebo; PPZ = perphenazine; QTP = quetiapine; RSP = risperidone; VPA = valproate; Zip = ziprasidone.
